HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Valette, H. Articles by Crouzel, C. Search for Related Content PubMed PubMed Citation Articles by Valette, H. Articles by Crouzel, C.

Myocardial Kinetics of the ¹¹C-Labeled Enantiomers of the Ca²⁺ Channel Inhibitor S11568: An In Vivo Study

Service Hospitalier Frédéric Joliot, Direction of Life Sciences, Department of Medical Research, French Atomic Agency, Orsay; and Institut de Recherche Servier, Suresnes, France

Ca²⁺ channels play a key role in the basic working of the heart. There is one particular type of Ca²⁺ channel in cardiac cells (L-type) whose gating is affected in different ways by ß-adrenoceptors and 1,4-dihydropyridines. In this study, we used ex vivo studies and PET to evaluate and compare the myocardial kinetics of the enantiomers labeled with ¹¹C (the more active: S12968, absolute configuration S; the less active: S12967, absolute configuration R) of the L-type Ca²⁺ channel antagonist S11568 (3-ethyl 5-methyl (±)-2-[(2-(2-aminoethoxy)ethoxy) methyl]-4-(2,3-dichlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate). Methods: [¹¹C]S12968 was injected into the tail vein of rats (0.22 kBq–5.92 MBq) to assess the relationship between injected dose and myocardial uptake. A series of 5 rats was pretreated with 4 µmol unlabeled S12968 5 min before injection of 2.2 kBq [¹¹C]S12968. In another series of 5 rats, unlabeled S12698 (4 µmol) was injected 5 min after injection of 2.2 kBq [¹¹C]S12968. The animals were killed 15 min later, and the myocardial radioactivity was assessed in a well counter. Beagle dogs received injections of 5–15 nmol [¹¹C]S12968 or [¹¹C]S12967 and were imaged with PET. Presaturation and displacement experiments using 2 µmol/kg unlabeled S12968 or 6 mol/kg S12967 were performed. Results: In rats, a statistically significant relationship between myocardial uptake and injected dose of S12968 was observed. Pretreatment or displacement with unlabeled S12968 reduced myocardial radioactivity by 75% and 70%, respectively. In dogs, after injection of 5 nmol of each enantiomer, myocardial radioactivity plateaued within 3 min and the clearance from blood was rapid. Injection of 13–15 nmol [¹¹C]S12968 led to a higher myocardial uptake and a more rapid washout, which were related to an increased coronary blood flow as shown by the linear relationship between k₁—an estimate of coronary blood flow—and the mass of S12968 injected. Presaturation and displacement experiments showed that 70%–80% of S12968 binding was specific. This specificity was not observed with S12967. Plasma metabolite analysis showed that 70% of the compound was unchanged 20 min after injection. Conclusion: These results show the feasibility of imaging myocardial L-type Ca²⁺ channels in vivo using [¹¹C]S12968.

Key Words: PET • heart • dihydropyridine binding • [¹¹C]S12968

This article has been cited by other articles:

				H. Valette, F. Dolle, I. Guenther, C. Fuseau, C. Coulon, F. Hinnen, J.-L. Peglion, and C. Crouzel In Vivo Quantification of Myocardial Dihydropyridine Binding Sites: A PET Study in Dogs J. Nucl. Med., September 1, 2002; 43(9): 1227 - 1233. [Abstract] [Full Text] [PDF]